And so that's exciting, right? 'Cause we're seeing new options come out even for patients where there's not really been good treatment options before.

And there's other trials going on as well.

For example, there's a trial going on right now, we call it OLOVEK or GOG 3076, and this is open.

What's really great about this particular trial is one, it's very novel, and two, it's open to patients who have had a lot of treatment before.

So many of our trials restrict prior lines of therapy to three or four.

In this particular trial, they're looking for patients who have had at least three prior treatments.

Now, you do have to be able to be eligible to receive bevacizumab, but basically it's an oncolytic virus.

Right.